{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,26]],"date-time":"2026-06-26T10:47:07Z","timestamp":1782470827608,"version":"3.54.5"},"reference-count":30,"publisher":"SAGE Publications","issue":"3","license":[{"start":{"date-parts":[[2026,4,21]],"date-time":"2026-04-21T00:00:00Z","timestamp":1776729600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/journals.sagepub.com\/page\/policies\/text-and-data-mining-license"}],"content-domain":{"domain":["journals.sagepub.com"],"crossmark-restriction":true},"short-container-title":["Substance Use &amp; Addiction Journal"],"published-print":{"date-parts":[[2026,7]]},"abstract":"<jats:p>In a drug landscape dominated by the highly potent synthetic opioid fentanyl, traditional methadone initiation protocols increasingly fail people with opioid use disorder (OUD). While \u201clow\u201d initial dose selection and \u201cslow\u201d dose adjustment rates reduce risk for methadone-associated toxicity, they also result in weeks to months of unrelieved withdrawal symptoms and cravings, especially for people with high opioid tolerance from routine fentanyl use. For this growing population, \u201clow-and-slow\u201d forces a choice between 3 poor options: suffer weeks to months of withdrawal, self-manage withdrawal through non-prescribed substance use, or give up on treatment. Our commentary combines a Peer Support Specialist\u2019s lived experiences with methadone initiation and evidence from the peer-reviewed literature to illustrate this problem and the role of one potential solution: rapid methadone initiation (RMI), defined here as reaching a methadone dose of 80\u2009mg or more within the first 7\u2009days of treatment. For appropriately selected patients, RMI is associated with positive outcomes, including improved patient satisfaction, reduced readmission rates, and increased retention in care. Though regulations permit and growing evidence supports RMI, adoption remains limited. Our commentary, therefore, concludes by sharing frameworks to support providers in implementing RMI as a potential treatment option for people with OUD across applicable care settings. Methadone\u2019s life-saving potential depends on dosing that matches the physiological reality of fentanyl use. Collectively, addiction clinicians define the community standard of care. In the face of a transformed drug landscape, it is time for that standard to evolve to ensure that the option for rapid and effective relief becomes the rule, rather than the exception.<\/jats:p>","DOI":"10.1177\/29767342261442052","type":"journal-article","created":{"date-parts":[[2026,4,22]],"date-time":"2026-04-22T05:54:32Z","timestamp":1776837272000},"page":"639-644","update-policy":"https:\/\/doi.org\/10.1177\/sage-journals-update-policy","source":"Crossref","is-referenced-by-count":0,"title":["Does Prolonged Suffering Have to Be a Part of the Process? Methadone Initiations in the Fentanyl Era: A Lived Experience Narrative, Evidence Review, and Call to Action"],"prefix":"10.1177","volume":"47","author":[{"given":"Brooke","family":"Jackson","sequence":"first","affiliation":[{"name":"Project Nurture, Portland, OR, USA"},{"name":"Adventist Health System, Portland, OR, USA"},{"name":"Fora Health, Portland, OR, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Patricia","family":"Liu","sequence":"additional","affiliation":[{"name":"Department of Medicine, Division of General Internal Medicine &amp; Geriatrics, Section of Addiction Medicine, Oregon Health &amp; Science University, Portland, OR, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-4304-3601","authenticated-orcid":false,"given":"David","family":"Lawrence","sequence":"additional","affiliation":[{"name":"Department of Mental Health, Veterans Affairs Greater Los Angeles Healthcare System, Los Angeles, CA, USA"},{"name":"Department of Medicine, David Geffen School of Medicine, UCLA, Los Angeles, CA, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"179","published-online":{"date-parts":[[2026,4,21]]},"reference":[{"key":"e_1_3_3_2_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.jsat.2022.108832"},{"key":"e_1_3_3_3_2","doi-asserted-by":"publisher","DOI":"10.1097\/ADM.0000000000000633"},{"key":"e_1_3_3_4_2","doi-asserted-by":"publisher","DOI":"10.1097\/ADM.0000000000001202"},{"key":"e_1_3_3_5_2","unstructured":"SAMHSA. TIP 63: medications for opioid use disorder. Published online October 11 2024. Accessed March 1 2026. https:\/\/www.samhsa.gov\/resource\/ebp\/tip-63-medications-opioid-use-disorder"},{"key":"e_1_3_3_6_2","doi-asserted-by":"publisher","DOI":"10.1097\/01.ADM.0000435321.39251.d7"},{"key":"e_1_3_3_7_2","doi-asserted-by":"publisher","DOI":"10.1377\/hlthaff.2019.01574"},{"key":"e_1_3_3_8_2","doi-asserted-by":"publisher","DOI":"10.1136\/bmj.j1550"},{"key":"e_1_3_3_9_2","doi-asserted-by":"publisher","DOI":"10.1001\/jamapsychiatry.2021.0976"},{"key":"e_1_3_3_10_2","doi-asserted-by":"publisher","DOI":"10.1046\/j.1360-0443.2000.951778.x"},{"key":"e_1_3_3_11_2","doi-asserted-by":"publisher","DOI":"10.1136\/bmj.39016.471840.68"},{"key":"e_1_3_3_12_2","doi-asserted-by":"publisher","DOI":"10.1136\/bmj.m772"},{"key":"e_1_3_3_13_2","doi-asserted-by":"publisher","DOI":"10.1097\/ADM.0000000000001473"},{"key":"e_1_3_3_14_2","unstructured":"Steiger S. Personal Communication. 2024."},{"key":"e_1_3_3_15_2","doi-asserted-by":"publisher","DOI":"10.1097\/ADM.0000000000001362"},{"key":"e_1_3_3_16_2","unstructured":"Van Dyke N. 2023 Nationwide opioid use disorder treatment outcomes report. Published online December 8 2023. Accessed March 1 2026. https:\/\/baymark.com\/blog\/2023-opioid-use-disorder-treatment-outcomes-report\/"},{"key":"e_1_3_3_17_2","doi-asserted-by":"publisher","DOI":"10.1097\/ADM.0000000000001339"},{"key":"e_1_3_3_18_2","doi-asserted-by":"publisher","DOI":"10.1097\/ADM.0000000000001548"},{"key":"e_1_3_3_19_2","doi-asserted-by":"publisher","DOI":"10.1186\/s40001-023-01538-0"},{"key":"e_1_3_3_20_2","doi-asserted-by":"publisher","DOI":"10.1097\/ADM.0000000000001629"},{"key":"e_1_3_3_21_2","doi-asserted-by":"publisher","DOI":"10.7326\/0003-4819-119-1-199307010-00004"},{"key":"e_1_3_3_22_2","doi-asserted-by":"publisher","DOI":"10.1007\/s00213-002-1027-0"},{"key":"e_1_3_3_23_2","unstructured":"SAMHSA. Federal guidelines for opioid treatment programs. Published online December 4 2024. Accessed August 19 2025. https:\/\/store.samhsa.gov\/sites\/default\/files\/federal-guidelines-opioid-treatment-pep24-02-011.pdf"},{"key":"e_1_3_3_24_2","doi-asserted-by":"publisher","DOI":"10.1001\/jamanetworkopen.2025.27290"},{"key":"e_1_3_3_25_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.jsat.2018.10.006"},{"key":"e_1_3_3_26_2","doi-asserted-by":"publisher","DOI":"10.1111\/j.1360-0443.2005.01232.x"},{"key":"e_1_3_3_27_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.drugalcdep.2005.01.013"},{"key":"e_1_3_3_28_2","doi-asserted-by":"publisher","DOI":"10.1001\/jamainternmed.2024.8586"},{"key":"e_1_3_3_29_2","doi-asserted-by":"publisher","DOI":"10.1001\/jamanetworkopen.2025.26077"},{"key":"e_1_3_3_30_2","unstructured":"Department of Health and Human Services SAMSHA. 42 CFR Part 8. Medications for the treatment of opioid use disorder. Published online February 2 2024. Accessed March 1 2026. https:\/\/public-inspection.federalregister.gov\/2024-01693.pdf"},{"key":"e_1_3_3_31_2","doi-asserted-by":"publisher","DOI":"10.1007\/s11606-016-3919-4"}],"container-title":["Substance Use &amp; Addiction Journal"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/journals.sagepub.com\/doi\/pdf\/10.1177\/29767342261442052","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/journals.sagepub.com\/doi\/full-xml\/10.1177\/29767342261442052","content-type":"application\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/journals.sagepub.com\/doi\/pdf\/10.1177\/29767342261442052","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,6,26]],"date-time":"2026-06-26T09:51:36Z","timestamp":1782467496000},"score":1,"resource":{"primary":{"URL":"https:\/\/journals.sagepub.com\/doi\/10.1177\/29767342261442052"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,4,21]]},"references-count":30,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2026,7]]}},"alternative-id":["10.1177\/29767342261442052"],"URL":"https:\/\/doi.org\/10.1177\/29767342261442052","relation":{},"ISSN":["2976-7342","2976-7350"],"issn-type":[{"value":"2976-7342","type":"print"},{"value":"2976-7350","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,4,21]]}}}